Normosang (Human Hemin)

Human Hemin, the active ingredient in Normosang, is a heme (heme derivative) presented as an injectable solution for intravenous use. It is employed to treat acute intermittent porphyria and other acute hepatic porphyrias by providing exogenous heme to patients experiencing metabolic attacks.

GNH USA supplies Normosang as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide, and clinics, ensuring consistent quality and regulatory compliance across markets. The product is manufactured under EU GMP standards and distributed through a secure cold‑chain logistics network.

Normosang is indicated for the management of acute hepatic porphyrias, where it helps restore heme levels and suppress toxic precursor accumulation. - Acute intermittent porphyria: reduces neurovisceral attacks by supplying heme and down‑regulating ALAS1. - Variegate porphyria: alleviates acute symptoms and limits porphyrin buildup. - Hereditary coproporphyria: mitigates crisis episodes through exogenous heme provision. - Other acute hepatic porphyrias: supports metabolic control during acute attacks.

Adverse reactions to Normosang may occur following intravenous administration.

Common Side Effects: - Injection site pain: mild discomfort at the infusion site. - Phlebitis: inflammation of the vein used for administration. - Transient fever: low‑grade temperature rise during or after infusion. - Nausea: occasional upset stomach. - Headache: mild to moderate headache post‑dose. - Elevated liver enzymes: temporary increase in hepatic transaminases.

Serious or Rare Side Effects: - Anaphylactic reaction: severe allergic response requiring immediate medical attention. - Hemolysis: breakdown of red blood cells leading to anemia. - Acute iron overload: excessive iron accumulation with repeated dosing. - Thrombophlebitis: clot formation with vein inflammation. - Severe hypotension: sudden drop in blood pressure during infusion.

When using Normosang, clinicians should observe several safety measures. - Monitor liver function: assess hepatic enzymes before and during therapy. - Assess iron status: check baseline ferritin and transferrin saturation. - Avoid in known hemin hypersensitivity: discontinue if allergic signs appear. - Use cautiously in renal impairment: monitor renal parameters closely. - Observe for infusion reactions: be prepared to manage anaphylaxis. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Normosang may interact with other agents that affect heme metabolism or iron balance.

Major Interactions (Avoid): - Concurrent iron dextran infusion: risk of precipitation and vascular irritation. - High‑dose vitamin C: may increase iron absorption and exacerbate overload.

Moderate Interactions (Monitor Closely): - Phenobarbital or other enzyme inducers: may alter porphyrin pathway dynamics. - Anticoagulants (e.g., warfarin): monitor coagulation parameters as hemin can affect platelet function. - Other heme‑based therapies: assess cumulative iron load and adjust dosing accordingly.